Immorta Bio Joins NYU Stern’s Endless Frontier Labs 2026-27 Cohort

Endless Frontier Labs operates as a nonprofit initiative designed to bridge the gap between academic innovation and market scale. By joining the nine-month program, Immorta Bio gains access to business coaches and Stern MBA students, resources the company intends to utilize as it moves away from preclinical development. The startup is currently focused on two therapeutic pillars: SenoMune™, an immunotherapy platform targeting senescent cells, and StemCellRevivify™, which aims to restore regenerative tissue function.

Boris N. Reznik, PhD, Chairman and CEO of Immorta Bio, stated that the selection serves as validation for the company’s underlying science. The program arrives at a pivotal juncture for the firm, which plans to leverage the EFL ecosystem to accelerate its entry into human clinical development. According to Thomas E. Ichim, PhD, President and Chief Scientific Officer, the company’s broader strategy involves targeting the core biological mechanisms of aging to address conditions ranging from oncology to organ failure.